Deciphera Pharmaceuticals, Inc.
DCPHDelisted Jun 11, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001654151
Deciphera Pharmaceuticals, Inc. was delisted on Jun 11, 2024; its insiders filed their last Form 4 on Jun 11, 2024; 177 institutions reported holding it in 13F filings for Q1 2024, worth $943.7M in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:51 PM ET
Revenue flow, FY2023
Where the revenue went in FY2023, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2023: $194.9M (119.3% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 8, 2024 | Jan 3, 2023 | Feb 8, 2022 | Feb 9, 2021 | Feb 12, 2020 |
| Revenue | $163.4M | $134.0M | $96.1M | $42.1M | $25.0M |
| Cost of revenue | $3.73M | $8.77M | $2.93M | $225.0K | – |
| Operating expenses | – | – | – | – | $225.7M |
| Research and development | $234.1M | $187.8M | $257.0M | $199.0M | $157.6M |
| Selling, general and administrative | $136.5M | $120.2M | $136.3M | $114.1M | $68.1M |
| Operating income | -$211.0M | -$182.7M | -$300.1M | -$271.2M | -$200.7M |
| Interest expense | – | – | $0 | $0 | $67.0K |
| Income tax | $431.0K | $0 | $0 | $0 | $0 |
| Net income | -$194.9M | -$178.9M | -$300.0M | -$266.5M | -$192.3M |
| EPS, basic | $-2.29 | $-2.37 | – | – | – |
| EPS, diluted | $-2.29 | $-2.37 | – | – | – |
| Weighted shares, basic | 85.1M | 75.5M | – | – | – |
| Weighted shares, diluted | 85.1M | 75.5M | – | – | – |
| Margins and growth | |||||
| Operating margin | -129.1% | -136.3% | -312.1% | -644.4% | -802.9% |
| Net margin | -119.3% | -133.5% | -312.0% | -633.2% | -769.0% |
| Revenue growth, year over year | +21.9% | +39.4% | +128.5% | +68.3% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 8, 2024 | Jan 3, 2023 | Feb 8, 2022 | Feb 9, 2021 | Feb 12, 2020 |
| Cash and equivalents | $83.5M | $64.7M | $87.1M | $135.9M | $120.3M |
| Short-term investments | $222.7M | – | – | – | – |
| Accounts receivable | $32.0M | $22.4M | $20.6M | $13.9M | – |
| Inventory | $21.2M | $20.6M | $14.1M | $5.72M | – |
| Total current assets | $381.1M | $393.0M | $339.0M | $584.0M | $593.4M |
| Property, plant and equipment | $5.42M | $6.71M | $8.61M | $9.58M | $6.33M |
| Total assets | $473.6M | $454.0M | $429.5M | $642.4M | $622.4M |
| Accounts payable | $26.5M | $18.6M | $13.1M | $12.3M | $19.6M |
| Total current liabilities | $100.3M | $86.5M | $96.8M | $70.0M | $60.0M |
| Total liabilities | $122.7M | $112.3M | $124.8M | $98.8M | $75.9M |
| Shareholders' equity | $350.9M | $341.7M | $304.7M | $543.7M | $546.5M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 8, 2024 | Jan 3, 2023 | Feb 8, 2022 | Feb 9, 2021 | Feb 12, 2020 |
| Operating cash flow | -$146.7M | -$152.9M | -$240.8M | -$239.7M | -$149.3M |
| Capital expenditures | $778.0K | $841.0K | $1.97M | $5.32M | $4.93M |
| Free cash flow | -$147.5M | -$153.7M | -$242.8M | -$245.0M | -$154.2M |
| Depreciation and amortization | $2.10M | $2.95M | $3.01M | $2.31M | $830.0K |
| Stock-based compensation | $50.6M | $51.9M | $46.1M | $37.1M | $20.4M |
| Investing cash flow | $12.5M | -$34.3M | $176.8M | $28.5M | -$460.5M |
| Financing cash flow | $152.0M | $165.0M | $14.9M | $226.8M | $436.4M |
| Net change in cash | – | -$22.2M | -$49.1M | $15.6M | -$173.4M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 31.0% | 38.8% | 47.9% | 88.2% | 81.6% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| May 6, 2024 | 86.5M | +10.1% | SEC |
| Jan 31, 2024 | 80.8M | +6.4% | SEC |
| Oct 26, 2023 | 80.1M | +18.6% | SEC |
| Jul 28, 2023 | 78.8M | +18.0% | SEC |
| Apr 28, 2023 | 78.5M | +18.6% | SEC |
| Jan 31, 2023 | 75.9M | +29.7% | SEC |
| Oct 28, 2022 | 67.6M | +15.6% | SEC |
| Jul 29, 2022 | 66.8M | +15.1% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.